Silent suppression for Antisense
Wednesday, 15 October, 2008
Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.
ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.
The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].
The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.
This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
